Skip to main content

Inhaled Cromolyn Sodium: Its Place in Asthma Management

Buy Article:

$39.50 plus tax (Refund Policy)


There has been a renewal of interest in inhaled drugs for the treatment of bronchial asthma in this country. Cromolyn sodium has been used as a first fine prophylactic agent in children with mild to moderate asthma with considerable success in our practice for the past several years. This report reviews previous clinical studies comparing cromolyn and theophylline, as well as a point by point pharmacologic comparison of these two agents. Reasons for previous treatment failures, and clinical guidelines to achieve maximum benefit with cromolyn are discussed.

Document Type: Research Article


Affiliations: University of Connecticut Medical School; Department of Pediatrics, Hartford Hospital, Hartford, CT

Publication date: 1984-12-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more